Drug Profile
HU 012
Alternative Names: HU012Latest Information Update: 19 Dec 2015
Price :
$50
*
At a glance
- Originator Huons
- Class Antihyperlipidaemics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Hyperlipidaemia
Most Recent Events
- 17 Dec 2015 No development reported - Preclinical for Hyperlipidaemia in South Korea (unspecified route)
- 31 Dec 2011 Preclinical trials in Hyperlipidaemia in South Korea (unspecified route) (Huons' pipeline, December 2015)